Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2849904 | American Heart Journal | 2015 | 12 Pages |
Abstract
Substituting the NCEP/ATP III cholesterol guidelines with the 2013 ACC/AHA cholesterol guidelines in MESA more than doubled the number of participants eligible for statin therapy. If the new ACC/AHA cholesterol guidelines are adopted and extend the primary prevention population eligible for treatment, the risk-benefit profile is much better for moderate-intensity than high-intensity statin treatment.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Joseph MD, MS, Stefan Sillau, Joseph C. Delaney, Michael J. Blaha, Erin D. Michos, Rebekah Young, Waqas T. Qureshi, Robyn McClelland, Gregory L. Burke, Bruce M. Psaty, David M. Herrington,